

National Stock Exchange of India

Circular

Department: LISTING

Download Ref. No.: NSE/CML/71376

Date: November 20, 2025

Circular Ref. No.: 2257/2025

To All Members,

Sub: Listing of equity shares of Beta Drugs Limited on Capital Market Segment (Main Board) pursuant to migration from SME Emerge platform

This has reference to our circular ref. no. NSE/CML/36085 dated October 11, 2017 regarding listing of equity shares of Beta Drugs Limited on SME EMERGE platform.

The members of the Exchange are hereby informed that the trading in equity shares of Beta Drugs Limited will be migrated from SME Platform (EMERGE) and admitted to dealings on the National Stock Exchange (Capital Market Segment – Main Board) with effect from November 24, 2025 and the designated security codes and lot size thereof shall be as specified in Annexure.

This circular shall be effective from November 24, 2025.

**For and on behalf of
National Stock Exchange of India Limited**

**Srishti Soni
Manager**

Annexure

Symbol	BETA
Name of the Company	Beta Drugs Limited
Series	EQ
ISIN	INE351Y01019
Face Value	Rs. 10/-
Paid-up Value	Rs. 10/-
Security Description	Equity shares of Rs. 10/- each fully paid up
No. of securities	10094553
Distinctive number range	1 to 10094553
Market lot	1
Pari Passu	Yes
Lock in details	Not Applicable

Address of Registered and Corporate Office of the Company:**Beta Drugs Limited**

Village Nandpur Baddi,
Himachal Pradesh-17410
Phone: 01795236196

Company Secretary: Ms. Rajni Brar
Web Site: www.betadrugslimited.com
Email id: cs@betadrugslimited.com
Financial Year: April 01 - March 31

Address of Registrar:

MUFG Intime India Private Limited
C-101, Embassy 247, L.B.S. Marg,
Vikhroli (West), Mumbai - 400083.
Website: www.in.mpms.mufg.com
E-mail: rnt.helpdesk@in.mpms.mufg.com